# Antifragile Treatment for Efficient Chimerism of Induced Pluripotent Stem Cells Derived Hematopoietic Stem Cells

## TL;DR

This study explores using antifragile treatment to improve the efficiency of producing transplantable blood stem cells from patient-specific stem cells.

## Contribution

The study introduces antifragile treatment with ginsenoside Rg1 to enhance the engraftment of iPSC-derived hematopoietic stem cells.

## Key findings

- iHSC differentiated with 1 µM Rg1 showed high colony-forming efficiency in vitro.
- High engraftment occurred in mice conditioned with 125 mg/kg busulfan.
- The method establishes a new source of HSC using patient-specific iPSC.

## Abstract

Engraftable hematopoietic stem cells (HSC) can be obtained from bone marrow, umbilical cord blood, and peripheral blood (PB). However, a major bottleneck in HSC transplantation is identifying an unrelated donor that completely matches the human leukocyte antigen type of the recipient. This issue can be resolved by producing patient-specific stem cells. The purpose of this study was to identify the conditions under which induced pluripotent stem cells (iPSC)-derived hematopoietic stem cells (iHSC) exhibit high efficiency. Because HSC are fragile and vulnerable to damage, this study was performed under the hypothesis that the engraftment rate could be increased by antifragile treatment. Antioxidant ginsenoside Rg1 was used to differentiate from iPSC to iHSC, and differentiated iHSC was intravenously injected into Balb/c nude mouse conditioned with diverse concentrations of busulfan. Engraftment was verified by the presence of human-specific markers in the PB at 2 and 8 weeks post iHSC transplantation. iHSC differentiated by incorporating 1 µM of Rg1 demonstrated high colony forming efficiency in vitro. Additionally, high efficiency engraftment occurred immediately after iHSC were transplanted into mice conditioned with high dose busulfan at a dosage of 125 mg/kg or higher. In this study, high-quality iHSC manufacturing and transplantation conditions capable of high efficiency engraftment in vivo were established. Hereafter, this method of producing HSC using patient-specific iPSC will become the fourth new source of HSC. Additionally, if gene-editing technology is applied, the scope of its application can be expanded to diverse infectious diseases.